Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Here is a link to an article that ran in The Seattle Times on Thursday under the headline "ZymoGenetics on track for final testing of key drug, Thrombin."

You may need to register to view it since it's now in the archives, but it's free if you do.

Some snippets are below...

Encouraged by earlier tests of a treatment for surgical bleeding, ZymoGenetics plans for the first time to take one of its drugs into the final phase of clinical testing.
The genetically engineered product, Thrombin, is important to ZymoGenetics strategically because it represents the company's initial attempt to develop on its own a product that could gain FDA approval.
Before spinning off as an independent public company in 2000, ZymoGenetics discovered several drugs now on the market, but those were taken through clinical trials at other companies......

ZymoGenetics isn't forecasting the market potential yet for its human version of Thrombin, but it said the cow-derived competitor is expected to reach $165 million in sales this year. Williams said Thrombin could conceivably be used for up to half a million surgeries a year in America, even though the cow-derived product isn't used that widely.
He said ZymoGenetics' product will likely be priced at a premium over the cow-derived version, which commonly sells for $150 per surgery.


Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.